George F. Vande Woude
#146,522
Most Influential Person Now
George F. Vande Woude's AcademicInfluence.com Rankings
George F. Vande Woudebiology Degrees
Biology
#10672
World Rank
#14022
Historical Rank
Microbiology
#598
World Rank
#666
Historical Rank
Molecular Biology
#1573
World Rank
#1601
Historical Rank
Download Badge
Biology
Why Is George F. Vande Woude Influential?
(Suggest an Edit or Addition)George F. Vande Woude's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. (1991) (2272)
- Transformation of mammalian cells by constitutively active MAP kinase kinase. (1994) (1448)
- Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. (1998) (997)
- Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer (2009) (529)
- Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. (1997) (524)
- Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. (1987) (520)
- Activating mutations for the met tyrosine kinase receptor in human cancer. (1997) (441)
- Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro (1993) (411)
- Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. (2001) (398)
- Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. (1994) (386)
- Met and hepatocyte growth factor/scatter factor expression in human gliomas. (1997) (355)
- The 3'-untranslated regions of c-mos and cyclin mRNAs stimulate translation by regulating cytoplasmic polyadenylation. (1994) (331)
- The product of the mos proto-oncogene as a candidate "initiator" for oocyte maturation. (1989) (327)
- Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network (1996) (327)
- HGF/SF‐met signaling in the control of branching morphogenesis and invasion (2003) (320)
- Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor (1992) (317)
- Properties of a normal mouse cell DNA sequence (sarc) homologous to the src sequence of Moloney sarcoma virus. (1980) (270)
- The met proto-oncogene receptor and lumen formation. (1992) (269)
- C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu (2005) (261)
- c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. (2007) (253)
- Nucleotide sequences of integrated Moloney sarcoma provirus long terminal repeats and their host and viral junctions. (1980) (241)
- The mutationally activated Met receptor mediates motility and metastasis. (1998) (233)
- Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway (1997) (232)
- The Mos/mitogen-activated protein kinase (MAPK) pathway regulates the size and degradation of the first polar body in maturing mouse oocytes. (1996) (218)
- Signaling pathways in Ras-mediated tumorigenicity and metastasis. (1998) (214)
- The Met proto-oncogene mesenchymal to epithelial cell conversion. (1994) (213)
- Structural basis of hepatocyte growth factor/scatter factor and MET signalling. (2006) (210)
- The von Hippel-Lindau Tumor Suppressor Gene Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Invasion and Branching Morphogenesis in Renal Carcinoma Cells (1999) (204)
- Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. (1998) (202)
- Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent (2013) (200)
- Expression and functional interaction of hepatocyte growth factor- scatter factor and its receptor c-met in mammalian brain (1994) (190)
- Potential role of mitogen-activated protein kinase during meiosis resumption in bovine oocytes. (1996) (180)
- The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. (2000) (177)
- High expression of the Met receptor in prostate cancer metastasis to bone. (2002) (176)
- Construction of a general human chromosome jumping library, with application to cystic fibrosis. (1987) (172)
- Mouse Mos protooncogene product is present and functions during oogenesis. (1989) (164)
- Proliferation and invasion: plasticity in tumor cells. (2005) (162)
- Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. (1988) (159)
- Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. (2005) (155)
- Human DNA sequence homologous to the transforming gene (mos) of Moloney murine sarcoma virus. (1982) (153)
- Hepatocyte Growth Factor Promotes Cancer Cell Migration and Angiogenic Factors Expression: A Prognostic Marker of Human Esophageal Squamous Cell Carcinomas (2005) (153)
- Met expression and sarcoma tumorigenicity. (1993) (151)
- Anthrax toxins (1999) (145)
- Showering c-MET-dependent cancers with drugs. (2008) (144)
- Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma. (2002) (143)
- c-mos proto-oncogene RNA transcripts in mouse tissues: structural features, developmental regulation, and localization in specific cell types (1987) (140)
- Proinvasion metastasis drivers in early-stage melanoma are oncogenes. (2011) (140)
- Hepatocyte growth factor is a synergistic factor for the growth of hematopoietic progenitor cells. (1992) (139)
- Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations (2007) (137)
- Pathogen-specific loss of host resistance in mice lacking the IFN-gamma-inducible gene IGTP. (2000) (135)
- Biological activity of cloned Moloney sarcoma virus DNA: Terminally redundant sequences may enhance transformation efficiency. (1980) (131)
- Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer (2009) (129)
- Protein kinase A acts at multiple points to inhibit Xenopus oocyte maturation (1994) (128)
- Ability of the c-mos product to associate with and phosphorylate tubulin. (1991) (127)
- Met-HGF/SF: tumorigenesis, invasion and metastasis. (2007) (126)
- Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability (1997) (126)
- Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells. (1996) (126)
- Construction and characterization of a recombinant plasmid encoding the gene for the thymidine kinase of Herpes simplex type 1 virus. (1979) (124)
- New method for detecting cellular transforming genes. (1982) (124)
- Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. (1990) (120)
- Analysis of the early embryonic cell cycles of Xenopus; regulation of cell cycle length by Xe-wee1 and Mos. (1998) (117)
- An activated rasN gene: detected in late but not early passage human PA1 teratocarcinoma cells. (1984) (116)
- Structure of varicella-zoster virus DNA (1981) (116)
- Positive feedback between MAP kinase and Mos during Xenopus oocyte maturation. (1996) (112)
- RNA Interference Reveals that Ligand-Independent Met Activity Is Required for Tumor Cell Signaling and Survival (2004) (111)
- Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma (2011) (110)
- Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. (2004) (109)
- Endosomal dynamics of Met determine signaling output. (2003) (108)
- Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor. (1993) (104)
- Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. (2001) (102)
- Characterization of human transforming genes from chemically transformed, teratocarcinoma, and pancreatic carcinoma cell lines. (1984) (102)
- Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways (2001) (101)
- MET: a critical player in tumorigenesis and therapeutic target. (2013) (101)
- Targeted disruption of Mig-6 in the mouse genome leads to early onset degenerative joint disease. (2005) (96)
- The Inducibly Expressed GTPase Localizes to the Endoplasmic Reticulum, Independently of GTP Binding* (1997) (93)
- Activation Mechanisms of the Urokinase-type Plasminogen Activator Promoter by Hepatocyte Growth Factor/Scatter Factor* (1999) (90)
- Mig-6, Signal Transduction, Stress Response and Cancer (2007) (90)
- Cloning of integrated Moloney sarcoma proviral DNA sequences in bacteriophage lambda. (1979) (89)
- Normalization and analysis of cDNA microarrays using within-array replications applied to neuroblastoma cell response to a cytokine. (2004) (84)
- Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. (1996) (84)
- Mig-6 modulates uterine steroid hormone responsiveness and exhibits altered expression in endometrial disease (2009) (81)
- Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. (1997) (81)
- MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. (2010) (81)
- Molecular cloning and physical mapping of varicella-zoster virus DNA. (1982) (80)
- Proto-oncogene expression in germ cell development. (1988) (79)
- Determination of v-Mos-catalyzed phosphorylation sites and autophosphorylation sites on MAP kinase kinase by ESI/MS. (1995) (78)
- Inhibition of mos-induced oocyte maturation by protein kinase A (1993) (77)
- Hepatocyte growth factor-stimulated invasiveness of monocytes. (2000) (76)
- Cloning of herpes simplex type 1 DNA fragments in a bacteriophage lambda vector. (1979) (73)
- Mos/mitogen-activated protein kinase can induce early meiotic phenotypes in the absence of maturation-promoting factor: a novel system for analyzing spindle formation during meiosis I. (1996) (73)
- Structures of two spliced herpes simplex virus type 1 immediate-early mRNA's which map at the junctions of the unique and reiterated regions of the virus DNA S component (1981) (73)
- Genes that Regulate Metastasis and Angiogenesis (2000) (71)
- The ras oncoprotein and M-phase activity. (1991) (71)
- Structural basis for agonism and antagonism of hepatocyte growth factor (2010) (70)
- A characterization of cytostatic factor activity from Xenopus eggs and c-mos-transformed cells (1991) (70)
- Mos and the cell cycle: the molecular basis of the transformed phenotype. (1993) (66)
- CENP-E is an essential kinetochore motor in maturing oocytes and is masked during mos-dependent, cell cycle arrest at metaphase II. (1997) (63)
- Expression of c‐met proto‐oncogene in COS cells induces the signal transducing high‐affinity receptor for hepatocyte growth factor (1992) (62)
- Chromosome instability drives phenotypic switching to metastasis (2016) (60)
- Met proto-oncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. (1995) (60)
- Sodium dodecylsulfate-dependent anomalies in gel electrophoresis: alterations in the banding patterns of foot-and-mouth disease virus polypeptides. (1974) (59)
- A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist (2007) (59)
- Signal transduction in c-met mediated motogenesis. (1993) (57)
- Evidence for non-covalent clusters of the c-met proto-oncogene product. (1992) (56)
- A highly invasive human glioblastoma pre-clinical model for testing therapeutics (2008) (55)
- Differential expression of c‐Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue (2007) (53)
- Generation of an autocrine leukaemia using a retroviral expression vector carrying the interleukin-3 gene. (1986) (52)
- Characterization of the rearranged tpr-met oncogene breakpoint (1987) (52)
- The Met-HGF/SF autocrine signaling mechanism is involved in sarcomagenesis. (1995) (51)
- Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome. (1992) (51)
- Chicken homolog of the mos proto-oncogene (1988) (49)
- DNA sequence of an immediate-early gene (IEmRNA-5) of herpes simplex virus type I. (1982) (49)
- Cartilage-specific deletion of Mig-6 results in osteoarthritis-like disorder with excessive articular chondrocyte proliferation (2014) (49)
- Nucleotide sequence and biochemical activities of the Moloney murine sarcoma virus strain HT-1 mos gene (1985) (47)
- Developmental regulation of ovarian-specific Mos expression. (1988) (47)
- Mouse c-mos oncogene activation is prevented by upstream sequences. (1984) (47)
- Alteration of Met protooncogene product expression and prognosis in breast carcinomas. (1999) (44)
- Defects in lens fiber differentiation are linked to c-mos overexpression in transgenic mice. (1987) (43)
- In vitro methylation of specific regions of the cloned Moloney sarcoma virus genome inhibits its transforming activity (1983) (42)
- Regulation of P311 Expression by Met-Hepatocyte Growth Factor/Scatter Factor and the Ubiquitin/Proteasome System* (2000) (42)
- The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. (1999) (42)
- Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma (2009) (41)
- Sequences upstream from the mouse c-mos oncogene may function as a transcription termination signal. (1986) (40)
- mos gene transforming efficiencies correlate with oocyte maturation and cytostatic factor activities (1991) (40)
- The decline in U.S. cancer mortality in people born since 1925. (2009) (39)
- Characterization of coliphage lambda hybrids carrying DNA fragments from Herpes simplex virus type 1 defective interfering particles. (1981) (39)
- Isolation of the structural polypeptides of foot-and-mouth disease virus and analysis of their C-terminal sequences. (1973) (38)
- Identification of a Met-Binding Peptide from a Phage Display Library (2007) (38)
- Mos positively regulates Xe-Wee1 to lengthen the first mitotic cell cycle of Xenopus. (1999) (38)
- Mos oncogene product associates with kinetochores in mammalian somatic cells and disrupts mitotic progression. (1994) (36)
- A p60 polypeptide in the feline leukemia virus pseudotype of Moloney sarcoma virus with murine leukemia virus p30 antigenic determinants. (1975) (36)
- Long terminal repeat enhancement of v-mos transforming activity: identification of essential regions (1983) (35)
- Physical map of the origin of defective DNA in herpes simplex virus type 1 DNA (1978) (35)
- Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. (1996) (34)
- Genetic analysis and developmental regulation of testis-specific RNA expression of Mos, Abl, actin and Hox-1.4. (1988) (33)
- Overexpression of mos oncogene product in Swiss 3T3 cells induces apoptosis preferentially during S-phase. (1995) (33)
- Human recipient cell for oncogene transfection studies (1987) (33)
- Studies on foot-and-mouth disease virus ribonucleic acid synthesis. (1966) (33)
- Neuropathological changes in transgenic mice carrying copies of a transcriptionally activated Mos protooncogene (1990) (33)
- Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy (2013) (32)
- Met decoys: will cancer take the bait? (2004) (32)
- Regulation of migration of primary prostate epithelial cells by secreted factors from prostate stromal cells. (2003) (31)
- MET and ERBB2 Are Coexpressed in ERBB2+ Breast Cancer and Contribute to Innate Resistance (2013) (30)
- Further linkage data on cystic fibrosis: the Utah Study. (1986) (29)
- Activation of mouse retrovirus by herpes simplex virus type 1 cloned DNA fragments. (1980) (28)
- Three additional DNA polymorphisms in the met gene and D7S8 locus: use in prenatal diagnosis of cystic fibrosis. (1987) (28)
- Characterization of integrated Moloney Sarcoma proviruses and flanking host sequences cloned in bacteriophage lambda. (1980) (28)
- Met-HGF/SF mediates growth arrest and differentiation in T47D breast cancer cells. (1999) (27)
- Mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. (1995) (27)
- Nuclear Imaging of Met-Expressing Human and Canine Cancer Xenografts with Radiolabeled Monoclonal Antibodies (MetSeekTM) (2005) (27)
- Persistent herpes simplex virus infections established in two Burkitt lymphoma derived cell lines. (1976) (27)
- Chromosomal localization of the Moloney sarcoma virus mouse cellular (c-mos) sequence (1982) (26)
- Frequent site-specific deletion of coliphage lambda murine sarcoma virus recombinants and its use in the identification of a retrovirus integration site (1980) (26)
- In vivo direct molecular imaging of early tumorigenesis and malignant progression induced by transgenic expression of GFP-Met. (2006) (26)
- Chemical and physical properties of foot-and-mouth disease virus: a comparison with Maus Elberfeld virus. (1972) (25)
- Radioimmunoscintigraphy of tumors autocrine for human met and hepatocyte growth factor/scatter factor. (2002) (25)
- Transduction of host cellular sequences by a retroviral shuttle vector (1986) (25)
- Strengthening Context-Dependent Anticancer Effects on Non–Small Cell Lung Carcinoma by Inhibition of Both MET and EGFR (2013) (24)
- In vitro and in vivo characterization of pp39mos association with tubulin. (1991) (22)
- The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution. (2008) (22)
- RhoA and RhoC Are Both Required for the ROCK II-Dependent Promotion of Centrosome Duplication (2010) (22)
- Geldanamycin derivative inhibition of HGF/SF-mediated Met tyrosine kinase receptor-dependent urokinase-plasminogen activation. (2005) (21)
- Chromosomal localization of the met proto-oncogene in the mouse and cat genome. (1987) (21)
- pp39mos is associated with p34cdc2 kinase in c-mosxe-transformed NIH 3T3 cells (1992) (20)
- tpr-met Oncogene Product Induces Maturation-Promoting Factor Activation in Xenopus Oocytes (1991) (20)
- Anthrax fusion protein therapy of cancer. (2002) (20)
- Cancer-Type Regulation of MIG-6 Expression by Inhibitors of Methylation and Histone Deacetylation (2012) (20)
- C-Met signalling in an HGF/SF-insensitive variant MDCK cell line with constitutive motile/invasive behaviour. (1996) (19)
- Two rearranged MET alleles in MNNG-HOS cells reveal the orientation of MET on chromosome 7 to other markers tightly linked to the cystic fibrosis locus. (1988) (18)
- High-level expression vectors to synthesize unfused proteins in Escherichia coli. (1986) (18)
- Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion (2011) (18)
- Similarities between somatic cells overexpressing the mos oncogene and oocytes during meiotic interphase. (1994) (18)
- Chemical determination of the m1 Moloney sarcoma virus pP60gag gene order: evidence for unique peptides in the carboxy terminus of the polyprotein. (1978) (18)
- Novel protein targeted therapy of metastatic melanoma. (2003) (17)
- BRAF and MEK Mutations Make a Late Entrance (2006) (17)
- A novel transposon-like repeat interrupted by an LTR element occurs in a cluster of B1 repeats in the mouse c-mos locus. (1984) (16)
- Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma (2015) (16)
- Quantitative imaging for development of companion diagnostics to drugs targeting HGF/MET (2016) (15)
- Mechanisms of Xenopus oocyte maturation. (1997) (15)
- Radioimmunoscintigraphy of human met-expressing tumor xenografts using met3, a new monoclonal antibody. (2003) (14)
- Structural Basis of TPR-Mediated Oligomerization and Activation of Oncogenic Fusion Kinases. (2017) (14)
- Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer (2010) (14)
- Inhibition of Host Cell Ribosomal Ribonucleic Acid Methylation by Foot-and-Mouth Disease Virus (1969) (14)
- Localization of the proto-oncogene MOS to 8q11-q12 by in situ chromosomal hybridization. (1988) (13)
- The long terminal repeat of Moloney sarcoma provirus. (1981) (13)
- Germline Met Mutations in Mice Reveal Mutation- and Background-Associated Differences in Tumor Profiles (2010) (13)
- Characterization of activated and normal mouse Mos gene in murine 3T3 cells. (1992) (13)
- The Mos proto-oncogene maps near the centromere on mouse chromosome 4. (1989) (13)
- Number and Molecular Weights of Foot-and-Mouth Disease Virus Capsid Proteins and the Effects of Maleylation (1971) (12)
- Autocrine mechanism for met proto-oncogene tumorigenicity. (1994) (12)
- The fractionation of histones by electrophoresis in polyacrylamide gel. (1965) (11)
- Ras oncogene-induced sensitization to 1-beta-D-arabinofuranosylcytosine. (1999) (11)
- Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody (2018) (11)
- Nucleoside triphosphate-dependent DNA-binding properties of mos protein. (1987) (11)
- Amino acid composition and C-terminal sequence of foot-and-mouth disease virus protein. (1968) (10)
- HGF/SF increases tumor blood volume: a novel tool for the in vivo functional molecular imaging of Met. (2006) (10)
- The met oncogene: a new member of the tyrosine kinase family and a marker for cystic fibrosis. (1986) (10)
- Ribosomal factors effecting the stimulation of cell-free protein synthesis in the prescence of foot-and-mouth disease virus ribonucleic acid. (1971) (10)
- Phosphorylation and nucleic acid binding properties of m1 Moloney murine sarcoma virus-specific pP60gag (1977) (10)
- Foot-and-Mouth Disease Virus-Induced Alterations of Baby Hamster Kidney Cell Macromolecular Biosynthesis: Inhibition of Ribonucleic Acid Methylation and Stimulation of Ribonucleic Acid Synthesis (1970) (10)
- Microinjection into Xenopus oocytes. (1995) (9)
- Tumorigenesis by transected cells in nude mice: a new method for detecting cellular transforming genes. (1983) (8)
- The human met oncogene is a member of the tyrosine kinase family. (1986) (7)
- Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding. (1995) (7)
- Inhibition of ribonucleic acid methylation in the foot-and-mouth disease virus-infected host cell. (1967) (7)
- Correlation between Physiological and Transforming Activities of the c–mos Proto–oncogene Product and Identification of an Essential Mos Domain for These Activities (1991) (7)
- Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer (2018) (7)
- MET4 expression predicts poor prognosis of gastric cancers with Helicobacter pylori infection (2017) (6)
- Growth of murine sarcoma and murine xenotropic leukemia viruses in Japanese quail: induction of tumors and development of continuous tumor cell lines. (1982) (6)
- mos proto-oncogene function. (1990) (5)
- Animal models for Ras-induced metastasis. (2001) (5)
- BARRIER ELECTROPHORESIS: A NEW ELECTROPHORESIS TECHNIQUE. (1963) (5)
- Analysis by pulsed field gel electrophoresis reveals complex rearrangements in two MET alleles in a chemically-treated human cell line, MNNG-HOS. (1990) (5)
- RTK inhibition: looking for the right pathways toward a miracle. (2012) (4)
- "A transgenic mouse model for men 2". (1992) (4)
- Mos and Ras: two oncoproteins that display M-phase activity. (1991) (3)
- The distinct stage-specific effects of 2-(p-amylcinnamoyl)amino-4-chlorobenzoic acid on the activation of MAP kinase and Cdc2 kinase in Xenopus oocyte maturation. (2005) (3)
- Embryology. On the loss of Mos. (1994) (3)
- Patterns of neoplasia in c-mos transgenic mice and their relevance to multiple endocrine neoplasia. (1992) (3)
- Properties of Moloney sarcoma virus-specific p60 and its detection in transformed cells. (1976) (3)
- The inactivation of foot-and-mouth disease virus at ionic-strength dependent isoelectric points. (1967) (2)
- tpr-met oncogene product induces maturation-producing factor activation in Xenopus oocytes (1991) (2)
- Developmental genetics and childhood cancer. AACR special conference in cancer research. (1991) (2)
- The long terminal repeat of Moloney sarcoma provirus enhances transformation. (1981) (2)
- The genetic basis of retroviral-induced transformation. (1982) (2)
- Genes involved in oncogenesis. (1997) (1)
- Advances in Cancer Research: Centennial Volume. Introduction. (2008) (1)
- Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma (2012) (1)
- Activation of the met proto-oncogene in a human cell line. (1987) (1)
- A cell-free mammalian protein-synthesizing system stimulated by RNA from avian myeloblastosis virus. (1975) (1)
- Screening and detection of breast cancer and prostate cancer. (2010) (0)
- On the loss of Mos (1994) (0)
- Properties of the met oncogene. (1986) (0)
- Ultrastructural study of herpes simplex virus infection of mouse cells chronically producing Rauscher leukemia virus. (1974) (0)
- Re: The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis. (1999) (0)
- Oncogenes and the Nobel Prize. (1990) (0)
- Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma (2015) (0)
- Search for oncogenicity of type C particles released from mammalian cell lines transformed by avian Oncornaviruses. (1974) (0)
- DNA markers for the cystic fibrosis locus. (1987) (0)
- Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody (2018) (0)
- Properties of the mouse mos proto-oncogene locus. (1987) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With George F. Vande Woude?
George F. Vande Woude is affiliated with the following schools:
